Orikine develops precision-engineered, bi-specific cytokines using a versatile protein-design platform to treat autoimmune and inflammatory diseases. Their Foldikine™ technology reprograms immune signaling by creating optimized cytokine therapeutics for targeted efficacy and safety. This approach aims to deliver precise immune modulation with enhanced durability and a higher therapeutic index.
Funding
$6.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MOFounders
Product
Problem
Immune-mediated diseases present significant therapeutic challenges due to the complex and often systemic nature of immune dysregulation. Current treatments often lack specificity, leading to broad immunosuppression and increased risk of adverse effects, while failing to fully address the underlying disease mechanisms.
Solution
Orikine Bio engineers cytokines with enhanced and unique biological properties to create targeted therapies for immune-mediated diseases. By precisely modulating the immune system, Orikine Bio's engineered cytokines aim to improve therapeutic efficacy and safety compared to traditional approaches. These novel cytokines are designed to selectively interact with specific immune cells and pathways, promoting a more balanced and controlled immune response. This targeted approach seeks to minimize off-target effects and maximize the therapeutic benefit for patients suffering from a range of immune-related disorders. The company's focus is on developing transformative therapies that can reshape the lives of patients worldwide.
Target Audience
Orikine Bio's primary target audience includes patients suffering from immune-mediated diseases, as well as pharmaceutical companies seeking innovative therapeutic options in the immunology space.
Features
- Engineered cytokines with tailored receptor binding profiles for enhanced specificity
- Modified cytokine structures designed for improved stability and pharmacokinetic properties
- Targeted immune modulation to selectively activate or suppress specific immune cell populations
- Preclinical validation demonstrating superior efficacy and safety compared to wild-type cytokines